Novartis may be planning to sell off its generics business Sandoz, but that hasn't stopped it investing in the unit ahead of a decision on its future later this year.
A London high court judge ruled this week that the damages paid to the NHS for an anticompetitive action by French pharma company Servier will not be reduced, despite an eyebrow-raising bid
Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on the possible sale of the unit m
Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines.
Graeme Duncan from ADVANZ PHARMA explores how successful cross-industry collaboration between pharma and generics companies has helped support supply challenges during the pandemic.